While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

This new edition of HCPLive’s monthly newsletter on recent US Food and Drug Administration (FDA) news features highlighted updates from across therapeutic pipelines.

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibody’s anti-inflammatory action.

The rheumatology month in review emphasizes new data from ACR 2024 in lupus, gout, and fibromyalgia.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

This Month in Review captures November updates in the psychiatry pipeline.

The biosimilars month in review highlights new equivalency data for denosumab and tocilizumab biosimilars.

Topline results from APPULSE-PNH show the positive efficacy and safety of twice-daily oral iptacopan in adults with PNH switched from anti-C5 therapies.

Andreas Kremer, MD, PhD, MHBA, explains seladelpar’s impact on pruritus in PBC based on findings from a posthoc analysis of the RESPONSE trial.

Andreas Kremer, MD, PhD, MHBA, reviews emerging therapies in PBC, focusing specifically on seladelpar and its impact on pruritus.

Andreas Kremer, MD, PhD, MHBA, explains shortcomings of traditional PBC therapies for addressing pruritus and what advantages newer agents may offer.

Andreas Kremer, MD, PhD, MHBA, describes the burden of pruritus in PBC and the toll it can take on patients’ quality of life.

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors are reshaping the evolving treatment landscape for chronic spontaneous urticaria (CSU) by providing targeted therapeutic options that address underlying mast cell activation.

Panelists discuss how patient education and shared decision-making are crucial in selecting appropriate therapies, as they empower patients to understand their treatment options and actively participate in their care.

A study found psilocybin therapy brings life-changing relief to depression symptoms triggered by clinicians’ frontline work during the COVID-19 pandemic.

Schattenberg reviews results from a posthoc analysis of the ENLIVEN study suggesting pegozafermin’s impact on preventing progression to cirrhosis.

A look into how SGLT2 inhibitors, GLP-1 RAs, and nsMRAs have redefined the management of cardio-kidney-metabolic diseases.

Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.

In this episode, hosts discuss the collaboration between Dexcom and Oura Ring, expanded compatibility of Omnipod 5 with Freestyle Libre 2, and Simplera CGM integration with the InPen.

In the fifth and final video from this series, experts discuss future research priorities and opportunities in hidradenitis suppurativa.

In part 4 of our series, expert dermatologists discuss the safety profile of bimekizumab in HS relative to other disease states and trials.

In this video series segment, expert dermatologsts prove ide insight into the strengths and limitations of IL-17 A/F inhibition in HS.

Expert dermatologists discuss the role of IL-17 A/F inhibition in the management of hidradenitis suppurativa.

In this 5-part, expert-led series, a pair of dermatologists break down how the FDA approval of bimekizumab impacts the treatment landscape of HS.